Reaction
Immune-Mediated Dermatitis reporting signals
As of the last recalculation, Immune-Mediated Dermatitis appears in 924 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 210.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ipilimumab | 281 | 210.3 | 211.7 |
| Pembrolizumab | 453 | 189.3 | 190.1 |
| Nivolumab | 353 | 132.5 | 133.0 |
| Pemetrexed | 74 | 84.4 | 84.7 |
| Durvalumab | 55 | 64.7 | 64.9 |
| Pemetrexed Disodium | 83 | 53.8 | 53.9 |
| Carboplatin | 223 | 51.8 | 51.9 |
| Paclitaxel (Aibumin-Bound) | 142 | 45.8 | 45.9 |
| Paclitaxel | 145 | 38.9 | 39.0 |
| Lenvatinib | 36 | 25.7 | 25.7 |
| Cisplatin | 52 | 15.8 | 15.8 |
| Fexofenadine Hcl | 6 | 14.7 | 14.7 |
| Atezolizumab | 22 | 13.0 | 13.1 |
| Cabozantinib | 19 | 9.1 | 9.1 |
| Gemcitabine Hydrochloride | 19 | 8.2 | 8.2 |